RhoGAP antibodies are essential tools for studying the Rho GTPase-activating protein (RhoGAP) family, which regulates Rho family GTPases (e.g., RhoA, Cdc42. Rac1) by accelerating their GTP hydrolysis, switching them to an inactive GDP-bound state. RhoGAPs play critical roles in cytoskeletal dynamics, cell migration, signaling, and homeostasis. Dysregulation of RhoGAP activity is linked to cancers, neurological disorders, and immune dysfunctions. Antibodies targeting RhoGAPs enable researchers to detect, quantify, and localize specific RhoGAP isoforms in cells or tissues, aiding in functional studies. These antibodies are validated for applications like Western blotting, immunofluorescence, and co-immunoprecipitation. Some are designed to recognize conserved catalytic domains, while others target unique epitopes to distinguish between closely related RhoGAP subtypes. Their specificity is crucial, as cross-reactivity may arise due to structural similarities among RhoGAP family members. Phospho-specific RhoGAP antibodies further help investigate post-translational modifications that modulate activity. Validating these antibodies using knockout controls or siRNA is standard practice. Commercially available RhoGAP antibodies often target well-characterized members like ARHGAP1. ARHGAP35 (GRAF), or DLC1. with applications in cancer research, neurobiology, and drug discovery. Proper selection depends on experimental goals, target isoforms, and sample compatibility.